HCW Biologics gets FDA clearance for Phase 1 trial of HCW9302 in alopecia areata

HCW Biologics Inc.

FDA cleared IND for HCW9302, a first-in-class IL-2 fusion protein, in moderate-to-severe alopecia areata.
Phase 1 dose-escalation trial will evaluate safety and T reg cell expansion via subcutaneous injection.
No curative FDA-approved treatments currently exist for alopecia areata.
Company plans to expand clinical development to other autoimmune diseases after Phase 1.
Founder and CEO Hing C. Wong called the clearance a milestone for the company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.